BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31189116)

  • 21. Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer.
    Zeng HZ; Qu YQ; Zhang WJ; Xiu B; Deng AM; Liang AB
    Int J Mol Sci; 2011; 12(6):3489-99. PubMed ID: 21747690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.
    Poupon MF; Arvelo F; Goguel AF; Bourgeois Y; Jacrot M; Hanania N; Arriagada R; Le Chevalier T
    J Natl Cancer Inst; 1993 Dec; 85(24):2023-9. PubMed ID: 7902445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
    Shaw GL; Gazdar AF; Phelps R; Steinberg SM; Linnoila RI; Johnson BE; Oie HK; Russell EK; Ghosh BC; Pass HI; Minna JD; Mulshine JL; Ihde DC
    J Cell Biochem Suppl; 1996; 24():173-85. PubMed ID: 8806100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy.
    Canitrot Y; Bichat F; Cole SP; Deeley RG; Gerlach JH; Bastian G; Arvelo F; Poupon MF
    Cancer Lett; 1998 Aug; 130(1-2):133-41. PubMed ID: 9751266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
    Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
    Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
    Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
    Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
    Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer.
    Kohmo S; Kijima T; Otani Y; Mori M; Minami T; Takahashi R; Nagatomo I; Takeda Y; Kida H; Goya S; Yoshida M; Kumagai T; Tachibana I; Yokota S; Kawase I
    Cancer Res; 2010 Oct; 70(20):8025-35. PubMed ID: 20940407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.
    Tan XL; Moyer AM; Fridley BL; Schaid DJ; Niu N; Batzler AJ; Jenkins GD; Abo RP; Li L; Cunningham JM; Sun Z; Yang P; Wang L
    Clin Cancer Res; 2011 Sep; 17(17):5801-11. PubMed ID: 21775533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of small cell lung cancer.
    Ciombor KK; Rocha Lima CM
    Curr Treat Options Oncol; 2006 Jan; 7(1):59-68. PubMed ID: 16343369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer.
    Oshita F; Ikehara M; Sekiyama A; Hamanaka N; Saito H; Yamada K; Noda K; Kameda Y; Miyagi Y
    J Exp Ther Oncol; 2004 Jul; 4(2):155-60. PubMed ID: 15500010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts.
    Arvelo F; Poupon MF; Bichat F; Grossin F; Bourgeois Y; Jacrot M; Bastian G; Le Chevalier T
    Eur J Cancer; 1995 Oct; 31A(11):1862-8. PubMed ID: 8541114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosomal alterations, biological features and in vitro chemosensitivity of SCLC-R1, a new cell line from human metastatic small cell lung carcinoma.
    Gasperi-Campani A; Roncuzzi L; Zoli W; Lenzi L; Gruppioni R; Sensi A; Zini N; Farabegoli F; Amadori D
    Eur J Cancer; 1998 Apr; 34(5):724-30. PubMed ID: 9713281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.